ClinicalTrials.gg
CompletedNCT01837251Updated Jul 13, 2021

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

A Phase 3 interventional study of Carboplatin and PLD in Recurrent Platinum-sensitive Ovarian Cancer, sponsored by AGO Research GmbH. Completed at 193 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-13.

Sponsored by AGO Research GmbH · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
682
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 166 studies testing carboplatin in Ovarian Neoplasms — 14 open to participants now, 21 under way, 6 of them phase 3. Carboplatin · Ovarian Neoplasms.

Enrollment
8th of 150
682 · median 48
Started
2013
with 3 others
Phase 3
25 of 166
4 open now
Registered
121st of 166
by date

Among the 166 studies testing carboplatin in Ovarian Neoplasms, this one is the 8th largest by enrollment of the 150 interventional ones that give a count, is one of 4 that started in 2013, is one of 25 in phase 3, and was the 121st registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

14 of the 166 studies testing carboplatin in Ovarian Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies testing carboplatin in Ovarian Neoplasms, or all of them as a file.
02

Study summary

Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.

03

Conditions studied

  • Recurrent Platinum-sensitive Ovarian Cancer

Browse trials for

Keywords

  • Ovarian Carcinoma
  • Bevacizumab
  • Gemcitabine
  • PLD
  • pegylated liposomal doxorubicin
  • Carboplatin
  • best therapeutic index
  • progression-free survival
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed diagnosis of epithelial ovarian carcinoma or fallopian tube carcinoma or primary peritoneal carcinoma
  2. First disease recurrence >6 months after platinum-based chemotherapy
  3. Patients with measurable or non- ( v1.1) or CA 125 assessable disease (GCIG criteria) or histological proven diagnosis of relapse
  4. In case of cytoreductive surgery for recurrence, patients must be able to commence cytotoxic chemo-therapy within 8 weeks after cytoreductive surgery
  5. PS 0-2
  6. >= 1.5 x 10\^9/L; >= 100 x 10\^9/L; >= 9.5 g/dL
  7. Patients not receiving anticoagulant medication who have an \<= 1.5 and an Activated ProThrombin Time \<= 1.5 x
  8. Serum \<= 2 x ULN; Serum transaminases \<= 2.5 x ULN (\<= 5 x ULN in the presence of liver )
  9. Serum creatinine \< 1.6 mg/dL or >= 40 mL/min; > 40 ml/min (estimates based on the Cockroft-Gault or Jelliffe formula); Urine dipstick for proteinuria \< 2+. If urine dipstick is >= 2+, 24 hour urine collection must demonstrate \<= 1 g of protein in 24 hours
  10. Normal blood pressure or adequately treated and controlled hypertension (either systolic BP ≤ 140 mmHg and/or diastolic BP ≤ 90 mmHg)

Exclusion criteria

Exclusion Criteria:

  1. Ovarian tumors of low malignant potential
  2. other than ovarian cancer within 5 years prior to randomization
  3. Administration of other simultaneous chemotherapy drugs, any other anticancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period
  4. Any previous radiotherapy to the abdomen or pelvis
  5. Known to used chemotherapeutic agents in this trial and bevacizumab and its , chinese hamster ovary cell products or other recombinant human or humanised antibodies
  6. Current or recent chronic use of aspirin > 325 mg/day
  7. Surgery (including open ) within 4 weeks prior to anticipated first dose of Bevacizumab
  8. History of VEGF therapy related abdominal fistula or gastrointestinal perforation
  9. Current, bowel obstruction, including sub-occlusive disease, related to underlying disease
  10. Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure
  11. Previous Cerebro-Vascular Accident , or Sub-Arachnoid Haemorrhage
  12. Prior history of hypertensive crisis or hypertensive encephalopathy
  13. Clinically significant disease, including: myocardial infarction or unstable angina within ≤ 6 months of randomization; (NYHA) >= grade 2 Congestive Heart Failure; poorly controlled cardiac arrhythmia despite medication; peripheral vascular disease grade >= 3
  14. defined by ECHO/MUGA below the institutional lower limit of normal
  15. Significant traumatic injury during 4 weeks prior to randomization
  16. Current or spinal cord compression
  17. History or evidence upon neurological examination of central nervous system disease
  18. Non-healing wound, active ulcer or bone fracture
  19. History or evidence of thrombotic or hemorrhagic disorders within 6 months prior to randomization
  20. Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic coagulation)
  21. Fertile woman of not willing to use adequate (oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) for the duration of the trial and at least 6 months afterwards
  22. Pregnant or lactating women
  23. Requirement of therapeutic anticoagulation using marcumar, warfarin or -prolonging heparin
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
682 participants (actual)

Study arms

  • No intervention
    Control Arm

    Patients receive bevacizumab 15 mg/kg iv on day 1 followed by gemcitabine 1000mg/m² iv on day 1 \& 8 and carboplatin AUC4 iv on day 1 every 3 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.

  • Experimental
    Research Arm

    Patients receive bevacizumab 10 mg/kg iv on day 1 \& 15 followed by PLD 30mg/m² iv on day 1 carboplatin AUC4 iv on day 1 every 4 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.

    Drug: Carboplatin · Drug: PLD · Biological: Bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. investigator-determined progression-free survival

    Time frame: every 12 weeks until progression or up to 30 months (whichever occurs first)

Secondary outcomes

  1. biological progression-free survival by serum CA 125

    Time frame: every 3 weeks until progression or up to 30 months (whichever occurs first)

  2. Health related Quality of Life (QoL)

    Time frame: Baseline and then every 12 weeks until investigator-determined progresssion-free survival and thereafter at every visit for th 5-years follow-up or death (whichever occurs first)

  3. Safety and Tolerability, i.e. type, frequency, severity and duration o adverse reactions

    Time frame: every 3 weeks, 30 months after start of treatment or if applicable 4 weeks after last dose of bevacizumab (whichever occurs later)

  4. Overall Survival

    Time frame: every 3 weeks during treatment with bevacizumab, thereafter every 6 months; for up 30 months

07

Study locations

193 sites
  • Bankstown-Lidcombe Hospital
    Bankstown, Australia
  • Chris O'Brien Lifehouse
    Camperdown, Australia
  • NCCI - Coffs Harbour Hospital
    Coffs Harbour, Australia
  • The Townsville Hospital
    Douglas, Australia
  • Peninsula Health - Frankston Hospital
    Frankston, Australia
  • Andrew Love Cancer Centre Geelong
    Geelong, Australia
  • Royal Brisbane & Women's Hospital
    Herston, Australia
  • Royal Hobart Hospital
    Hobart, Australia
  • St. George Hospital
    Kogarah, Australia
  • ICON Cancer Care Centre
    Milton, Australia
  • Nambour General Hospital
    Nambour, Australia
  • Sir Charles Gairdner
    Nedlands, Australia
  • North Coast Cancer Institute
    Port Macquarie, Australia
  • Royal Hospital for Women
    Randwick, Australia
  • Mater Adult Hospital
    South Brisbane, Australia
  • Gold Coast University Hospital
    Southport, Australia
  • Royal North Shore Hospital
    St. Leonards, Australia
  • St. John of God Hospital
    Subiaco, Australia
  • Border Medical Oncology
    Wodonga, Australia
  • MUG-Universitätsklinik für Frauenheilkunde Graz
    Graz, Austria
  • MUI-Universität für Frauenheilkunde
    Innsbruck, Austria
  • AKH Linz
    Linz, Austria
  • BHS Linz
    Linz, Austria
  • SALK-LKH Salzburg, Universitätsklinik für Frauenheilkunde und Geburtshilfe
    Salzburg, Austria
  • MUW-AKH Wien
    Wien, Austria
  • UZ Leuven
    Leuven, Belgium
  • ICO Paul Papin
    Angers, France
  • Institut Sainte Catherine
    Avignon, France
  • Centre Hospitalier de Blois
    Blois, France
  • Clinique Tivoli
    Bordeaux, France
  • Polyclinique Bordeaux Nord
    Bordeaux, France
  • Centre Francois Baclesse
    Caen, France
  • Centre Hospitalier William Morey
    Chalon-Sur-Saone, France
  • Centre Hospitalier de Cholet
    Cholet, France
  • Hôpital Antoine Béclère
    Clamart, France
  • Centre Jean Perrin
    Clermont-Ferrand, France
  • Centre Hospitalier la Dracénie
    Draguignan, France
  • Centre Hospitalier Général de Gap
    Gap, France
  • Groupe Hospitalier Mutualiste de Grenoble
    Grenoble, France
  • Hôpital Michallon, Centre Hospitalier Universitaire de Grenoble
    Grenoble, France
  • Centre Hospitalier Départemental Les Oudairies
    La Roche sur Yon, France
  • Institut d'Oncologie Hartmann
    Levallois-Perret, France
  • Centre Oscar Lambret
    Lille, France
  • Hôpital Privé Clairval
    Marseille, France
  • Institute Paoli Clamettes
    Marseille, France
  • Hôpital Mercy
    Metz, France
  • Hôpital de Mont-de-Marsan
    Mont de Marsan, France
  • ICM Val d'Aurelle
    Montpellier, France
  • Hôpital Emile Muller
    Mulhouse, France
  • Centre d'Oncologie de Gentilly
    Nancy, France
  • Centre Catherine de Sienne
    Nantes, France
  • Centre Hospitalier Régional d'Orleans
    Orleans, France
  • Group Hospitalier Saint-Joseph
    Paris, France
  • Centre Catalan d'Oncologie
    Perpignan, France
  • Clinique Francheville
    Périgueux, France
  • Centre Eugène Marquis
    Rennes, France
  • HôpitauxDrôme Nord - Site de Ramons
    Romans-sur-Isère, France
  • Centre Henri Becquerel
    Rouen, France
  • Clinique Armoricaine de Radiologie
    Saint Brieuc, France
  • ICO Centre René Gauducheau
    Saint Herblain, France
  • Clinique Mutualiste de l'Estuaire, Cité Sanitaire
    Saint Nazaire, France
  • Centre Paul Strauss
    Strasbourg, France
  • Hôpitaux Universitaires de Strasbourg
    Strasbourg, France
  • Centre Hospitalier de Thonon-les-Bains
    Thonon-les-Bains, France
  • Clinique Pasteur
    Toulouse, France
  • Clinique Saint Jean du Languedoc
    Toulouse, France
  • Centre Hospitalier Bretagne Atlantique
    Vannes, France
  • Hôpital Privé Villeneuve d'Ascq, Institut de Canérologie
    Villeneuve d'Ascq, France
  • Kreisklinik Altötting-Burghausen
    Altötting, Germany
  • Klinikum St. Marien
    Amberg, Germany
  • Klinikum Aschaffenburg
    Aschaffenburg, Germany
  • Klinikum Augsburg
    Augsburg, Germany
  • Hochtaunus-Klinik
    Bad Homburg, Germany
  • Charité - Universitätsmedizin Berlin
    Berlin, Germany
  • HELIOS Klinikum Berlin-Buch
    Berlin, Germany
  • Praxisklinik Krebsheilkunde für Frauen
    Berlin, Germany
  • Augusta-Kranken-Anstalt Bochum
    Bochum, Germany
  • Johanniter-Krankenhaus
    Bonn, Germany
  • Medizinisches Zentrum Bonn-Friedensplatz
    Bonn, Germany
  • Schwerpunktpraxis für Onkologie / Hämatologie
    Bottrop, Germany
  • Städtisches Klinikum Brandenburg
    Brandenburg, Germany
  • Gynäkologisch-Onkologische Gemeinschaftspraxis
    Braunschweig, Germany
  • DIAKO Ev. Diakonie-Krankenhaus
    Bremen, Germany
  • Gynaekologicum Bremen
    Bremen, Germany
  • Klinikum Bremen-Mitte
    Bremen, Germany
  • Klinikum Chemnitz
    Chemnitz, Germany
  • Klinikum Darmstadt
    Darmstadt, Germany
  • Donau-Isar-Kliniken, Klinikum Deggendorf
    Deggendorf, Germany
  • Städtisches Klinikum Dessau
    Dessau, Germany
  • Klinikum Dortmund
    Dortmund, Germany
  • Onkozentrum Dresden
    Dresden, Germany
  • Universitätsklinikum Carl Gustav Carus
    Dresden, Germany
  • Evangelisches Krankenhaus Düsseldorf
    Düsseldorf, Germany
  • Kaiserswerther Diakonie, Florence-Nightingale-Krankenhaus
    Düsseldorf, Germany
  • Universitätsfrauenklinik Düsseldorf
    Düsseldorf, Germany
  • Rottal-Inn-Klinik Eggenfelden
    Eggenfelden, Germany
  • Universitätsklinikum Erlangen
    Erlangen, Germany
  • Klinikum Essen Mitte
    Essen, Germany
  • Universitätsklinikum Essen
    Essen, Germany
  • Klinikum Esslingen
    Esslingen, Germany

Showing the first 100 of 193 sites across 6 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marme F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. Erratum In: Lancet Oncol. 2022 Jun;23(6):e248. doi: 10.1016/S1470-2045(22)00303-5. PubMed 32305099 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2013 to primary completion in Jan 2021, 92 months.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 92 months is above that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2013
First posted
Apr 23, 2013
StartActual
May 2013
Primary completionActual
Jan 2021
CompletionActual
Jan 2021
Last update
Jul 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01837251
Lead sponsor
AGO Research GmbH
Collaborators
Arbeitsgemeinschaft Gynaekologische Onkologie Austria, ARCAGY/ GINECO GROUP, Australia New Zealand Gynaecological Oncology Group, Scottish Gynaecological Cancer Study Group
Responsible party
Sponsor
First posted
Apr 23, 2013
Start date
May 2013
Primary completion
Jan 2021
Completion
Jan 2021
Last update
Jul 13, 2021

Study contacts

Jacobus Pfisterer, PhD MD
study chair · AGO Study Group

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboplatin · Bevacizumab

Start the discussion